Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-8068 in Combination Anti-tumor Drugs for Advanced Renal Cell Carcinoma
NCT07239596Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jan 2026
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CS1002 in renal cell carcinoma (RCC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Jan 2026; status: recruiting.
02
Drugs
CS1002
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07239596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239596.